

Use of electrocardiogram monitoring in adult patients taking high-risk QT interval prolonging medicines in clinical practice: systematic review and meta-analysis

Electronic Supplementary Material 3

Assessment of Methodological Quality using JBI Critical Appraisal Tool

Drug Safety

Marijana Putnikovic,^{1,2} Zoe Jordan,¹ Zachary Munn,¹ Corey Borg,^{1,2} Michael Ward^{3,4}

1. JBI, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia
2. SA Pharmacy Medicines Information Service, Adelaide, Australia
3. Clinical and Health Sciences, University of South Australia, Adelaide, Australia
4. Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Adelaide, Australia

Corresponding author: Marijana Putnikovic, JBI, Faculty of Health and Medical Sciences, The University of Adelaide, 55 King William Road, SA 5006 North Adelaide, Australia, Email: marijana.putnikovic@adelaide.edu.au.

Supplementary Material 3

Assessment of Methodological Quality using JBI Critical Appraisal Tool

Included studies	Q1	Q2	Q3	Q4*	Q5	Q6	Q7*	Q8	Q9	Score	Quality assessment
Cole et al [1] 2020	Y	Y	Y	Y	U	Y	Y	Y	N	7	High quality
Pezo et al [2] 2019	N	Y	Y	N	Y	Y	Y	Y	N	6	Poor quality
Manchia et al [3] 2017	Y	Y	N	Y	Y	Y	U	N	U	5	Poor quality
Ehrenpreis et al [4] 2016	Y	Y	N	Y	Y	Y	Y	Y	U	7	High quality
Atayee et al [5] 2017	Y	Y	N	Y	U	Y	Y	Y	Y	7	High quality
Vandael et al [6] 2016	Y	Y	N	Y	Y	Y	Y	Y	Y	8	High quality
Robbins et al [7] 2016	Y	Y	N	Y	U	U	Y	Y	Y	6	Poor quality
Girgis et al [8] 2016	Y	Y	N	Y	U	U	Y	Y	Y	6	Poor quality
Forbes et al [9] 2016	Y	Y	N	Y	Y	Y	Y	Y	U	7	High quality
Dunker et al [10] 2016	Y	Y	N	Y	Y	Y	U	Y	Y	7	Poor quality
Choo et al [11] 2014	Y	Y	N	Y	U	Y	Y	Y	U	6	Poor quality
Macey et al [12] 2013	Y	Y	N	Y	N	Y	Y	Y	U	6	Poor quality
Cheung et al [13] 2013	N	Y	N	Y	U	U	Y	Y	U	4	Poor quality
Muzyk et al [14] 2012	Y	Y	N	Y	U	U	Y	N	Y	5	Poor quality

*Domains that needed both to be Y in order to be eligible for high quality status

Studies were rated as Yes (Y), No (N), or Unclear (U) for each question.

An unclear rating indicates that the details either could not be located in the article or could not be clarified with the author.

Appraisal criteria for prevalence studies:

Q1 Was the sample frame appropriate to address the target population? **Q2** Were the study participants sampled in an appropriate way? **Q3** Was the sample size adequate? **Q4** Were the study subjects and the setting described in detail? **Q5** Was the data analysis conducted with sufficient coverage of the identified sample? **Q6** Were valid methods used for the identification of the condition? **Q7** Was the condition measured in a standard, reliable way for all participants? **Q8** Was there appropriate statistical analysis? **Q9** Was the response rate adequate, and if not, was the low response rate managed appropriately?

References

1. Cole, J.B., et al., *The incidence of QT prolongation and torsades des pointes in patients receiving droperidol in an urban emergency department*. Western Journal of Emergency Medicine, 2020. **21**(4): p. 728-736.
2. Pezo, R.C., et al., *Underuse of ECG monitoring in oncology patients receiving QT-interval prolonging drugs*. Heart, 2019. **105**(21): p. 1649-1655.
3. Manchia, M., et al., *Clinicians' adherence to clinical practice guidelines for cardiac function monitoring during antipsychotic treatment: A retrospective report on 434 patients with severe mental illness*. BMC Psychiatry, 2017. **17**(1): p. 121.

4. Ehrenpreis, E.D., et al., *Domperidone is Commonly Prescribed With QT-Interacting Drugs: Review of a Community-based Practice and a Postmarketing Adverse Drug Event Reporting Database*. J Clin Gastroenterol, 2017. **51**(1): p. 56-62.
5. Atayee, R.S., et al., *Methadone Inpatient and Discharge Prescribing Patterns for Pain at an Academic Health System*. Journal of Palliative Medicine, 2017. **20**(2): p. 184-192.
6. Vandael, E., et al., *Risk management of QTc-prolongation in patients receiving haloperidol: an epidemiological study in a University hospital in Belgium*. International Journal of Clinical Pharmacy, 2016. **38**(2): p. 310-320.
7. Robbins, N.M., et al., *Safety of domperidone in treating nausea associated with dihydroergotamine infusion and headache*. Neurology, 2016. **87**(24): p. 2522-2526.
8. Girgis, S.J., M.E. Maroney, and M.T. Liu, *Evaluation of the use of electrocardiogram monitoring in patients on psychotropic medications that have a risk of QT prolongation*. Ment Health Clin, 2016. **6**(4): p. 171-177.
9. Forbes, N., et al., *Domperidone Prescribing Practices Exposed Patients to Cardiac Risk despite a "black Box" Warning: A Canadian Tertiary Care Center Study*. Canadian Journal of Gastroenterology and Hepatology, 2016. **2016**: p. 2937678.
10. Dunker, A., et al., *Impact of the FDA Warning for Azithromycin and Risk for QT Prolongation on Utilization at an Academic Medical Center*. Hospital Pharmacy, 2016. **51**(10): p. 830-833.
11. Choo, W.K., et al., *Prescribers' practice of assessing arrhythmia risk with QT-prolonging medications*. Cardiovascular Therapeutics, 2014. **32**(5): p. 209-213.
12. Macey, T.A., et al., *Patterns of care and side effects for patients prescribed methadone for treatment of chronic pain*. Journal of Opioid Management, 2013. **9**(5): p. 325-333.
13. Cheung, D., et al., *Unsafe use of intravenous haloperidol: Evaluation of recommendation-concordant care in hospitalized elderly adults*. Journal of the American Geriatrics Society, 2013. **61**(1): p. 160-161.
14. Muzyk, A.J., et al., *A computerized physician order entry set designed to improve safety of intravenous haloperidol utilization: A retrospective study in agitated hospitalized patients*. Drug Safety, 2012. **35**(9): p. 725-731.